Document is current

Any future updates will be listed below

Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

Crossref DOI link: https://doi.org/10.1007/s00262-016-1861-2

Published Online: 2016-06-24

Published Print: 2016-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark